Kanion Pharmaceutical
Launch date
Employees
Market cap
AUD1.5b
Enterprise valuation
AUD1.2b (Public information from Sep 2024)
Share price
CNY12.15 600557.SS
Nanjing City Jiangsu (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 3.0b | 3.6b | 4.4b | 4.9b | 4.9b | 6.3b | 7.1b |
| % growth | (34 %) | 20 % | 19 % | 12 % | 1 % | 28 % | 14 % |
| EBITDA | 476m | 523m | 638m | 740m | 683m | 925m | 1.0b |
| % EBITDA margin | 16 % | 14 % | 15 % | 15 % | 14 % | 15 % | 15 % |
| Profit | 263m | 321m | 434m | 537m | 557m | 744m | 873m |
| % profit margin | 9 % | 9 % | 10 % | 11 % | 11 % | 12 % | 12 % |
| EV / revenue | 2.0x | 1.9x | 2.5x | 2.5x | 1.6x | 1.2x | 1.1x |
| EV / EBITDA | 12.7x | 13.5x | 17.2x | 16.2x | 11.2x | 8.2x | 7.3x |
| R&D budget | 380m | 499m | 606m | 772m | - | - | - |
| R&D % of revenue | 13 % | 14 % | 14 % | 16 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | - | |
| N/A | N/A | IPO | |
| Total Funding | - | ||
